Company intelligence / Profile preview

Gold Standard Diagnostics

Frankfurt, Hesse, Germanygoldstandarddiagnostics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Gold Standard Diagnostics provides automated platforms and an extensive menu of diagnostic tests for clinical laboratories worldwide. Their portfolio includes ELISA kits, PCR assays, lateral flow devices and automation solutions for virology, bacteriology, parasitology, mycology, hormones/endocrinology testing, autoimmune diseases and oncology. They have received FDA clearance for certain products (e.g., Lyme disease EIA) and CE-IVD marking for many others. The group emphasizes innovation in assay development with global reach across over 85 countries.

Modalities: Diagnostic test kitELISA-based diagnosticsPCR-based diagnosticsLateral flow assay (LFA)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Gold Standard Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gold Standard Diagnostics.

Explore the full profile